Not yet taking people in United StatesPhase 4

Testing and treating hepatitis C in one emergency department visit

Tests same-visit hepatitis C treatment with Epclusa and adherence support for emergency patients.

Key facts

Who runs it: Patrick Grace
Where: Lexington, United StatesSee the site
Trial code: NCT07793643
Registry title: AI-Powered Hepatitis C Single-Encounter Test-and-Treat
Status: Not yet recruiting
Phase: Phase 4
People taking part: 35 people, planned
Starts: 1 Dec 2026
Expected to end: 1 Sept 2028
Type of study: Interventional
Treatments tested: Epclusa (sofosbuvir and velpatasvir)
Record updated: 28 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with hepatitis C seen in the emergency department who are going home the same day. They get testing and hepatitis C medicine in one visit, with support to take it.

Age: 22 to 65 years
Sex: All sexes
Disease stage: Hepatitis C without known cirrhosis (scarring of the liver).
Biomarker or test result: Hepatitis C antibody testing as part of routine screening in the emergency department.

Main reasons for not taking part

Known cirrhosis shown by blood tests, imaging, platelet count <150,000/m3 or liver biopsy
Known or suspected liver cancer (hepatocellular carcinoma)
Pregnancy
Chronic kidney disease or being on dialysis
Being admitted to the hospital, highest-urgency patients (ESI Level one), or life expectancy < 1 year

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

Age 22-65 years old, presenting to the Emergency Department (ED) who are undergoing antibody testing as part of universal screening
Patients to be discharged from the ED or ED Observational units

Who cannot take part

Known prior liver biopsy showing cirrhosis; •Pregnancy
Followed by hospice or transplant, have a life expectancy < 1 year
Chronic Kidney Disease (CKD) or on dialysis
Allergy to study medications
Known clinical evidence of cirrhosis (egliver nodularity and/or splenomegaly on imaging, platelet count <150,000/m3, etc.)
Capacity to Consent
Emergency Severity Index (ESI) Level one (high acuity patients)
Known noninvasive serologic tests above proprietary cutoffs indicating cirrhosis (example - FibroSure, Enhanced Liver Fibrosis Test, etc.)
Known or suspected Hepatocellular carcinoma
Patients admitted to the hospital

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

Are you between 22 and 65 years old?

Where in United States

University of KentuckyLexington, United StatesContact: Patrick GraceNot yet recruiting

About the trial

What the trial wants to find out

This study will evaluate a single-visit approach to hepatitis C treatment in patients seen in the emergency department. Participants with hepatitis C will receive rapid testing and, if eligible, hepatitis C medication before leaving the emergency department. The study will also use a smart pillbox, an AI-powered virtual agent, and community health worker support to help participants take their medication as prescribed. Participants will have follow-up visits and testing to assess medication adherence and whether the hepatitis C infection is cured.

The group in the trial

Medication in HandTreatment being tested
Participants will receive hepatitis C treatment during the emergency department visit, along with medication adherence support using a cellular-connected smart pillbox, an artificial intelligence-powered virtual agent, and community health worker support. Participants will be followed through treatment completion and follow-up testing.
Treatment: Epclusa (sofosbuvir and velpatasvir)